Nagoya, Japan – October 24th, 2018 – PharmaBio Corporation delighted to announce that we had a ceremony to celebrate the completion of brand-new cell factory in October 17th, 2018. In addition, we announce that the cell factory preview party was held in October 18th, 2018. The factory is located in Tonomachi International Strategic Zone “KING SKYFRONT” in Kawasaki, Kanagawa.
The ceremony was held in accordance with Japanese traditional style with attendance of about 40 guests, followed by factory tour. There were more than 100 attendees to the party from various academia, government and industries.
The factory will start operation in early 2019. Once started, our manufacturing capacity increases much, and it enables accelerating development of Regenerative Medicine/ Cell Therapy products. We strive to contribute to patients who are waiting for novel therapies by operating the factory.
【About PharmaBio】
PharmaBio (CEO: Hitoshi Kusano, headquarter: Nagoya City), as Japan’s first contract development and manufacturing organization for specialized in cell and tissue-derived pharmaceuticals, provides pharmaceutical development solution business and contract manufacturing of cell and tissue based products and which achieves highly quality and high effectiveness in manufacturing development process.
In addition, we will respond to the development manufacturing consignment for Global Study through a service provision alliance with Cell Therapies pty. Ltd., which is known as leading CDMO in the Asia Pacific region in the cell / tissue derived medicine field.
PharmaBio (CEO: Hitoshi Kusano, headquarter: Nagoya City), as Japan’s first contract development and manufacturing organization for specialized in cell and tissue-derived pharmaceuticals, provides pharmaceutical development solution business and contract manufacturing of cell and tissue based products and which achieves highly quality and high effectiveness in manufacturing development process.
In addition, we will respond to the development manufacturing consignment for Global Study through a service provision alliance with Cell Therapies pty. Ltd., which is known as leading CDMO in the Asia Pacific region in the cell / tissue derived medicine field.